Navigation Links
Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
Date:10/6/2009

rements and activities mentioned above, and assuming that no events occur which could cause further delay.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha- 2b. Helix is listed on the TSX and FSE under the symbol "HBP" and the OTCQX International Market under the symbol "HXBPF".

For further information contact:

    Investor Relations                 Media Relations
    Robert Flamm, Ph.D.                Ian Stone
    Russo Partners LLC                 Russo Partners LLC
    Tel: (212) 845-4226                Tel: (619) 814-3510
    Email:
    robert.flamm@russopartnersllc.com  Fax: (619) 955-5318
    www.russopartnersllc.com           Email: ian.stone@russopartnersllc.com

Forward-Looking Statements and Risks

This News Release contains certain forward-looking statements and forward-looking information, within the meaning of applicable securities laws, regarding the Company's development programs for Topical Interferon Alpha-2b and L-DOS47, including the Company's expected timing of anticipated IND filings in the United States, of completing the minimum required number of patients for the pharmacokinetic study in Germany, of the completion date for the AGW trial, and of the completion of necessary batch manufacturing and stability testing. Other forward-looking statements and information relate to, among other things, the Company's plans to
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
4. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
5. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
6. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
7. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014  NxStage Medical, Inc. (Nasdaq: ... announced that Jeffrey H. Burbank , Chief Executive Officer, ... at the 34 th Annual Canaccord Genuity Growth Conference ... , on Wednesday, August 13 th at 4:30 ... available at http://ir.nxstage.com/ .  About NxStage ...
(Date:8/1/2014)... HYDERABAD, India , Aug. 1, 2014 /PRNewswire/ ... manufacturer providing active pharmaceutical ingredients (APIs), ... to customers located in 85 countries, today announced ... year (FY) 2015, ended June 30, 2014. ... affected by work flow re-prioritization to accommodate certain ...
(Date:8/1/2014)... JUPITER, Fla. , Aug. 1, 2014 ... company whose patented and proprietary technologies are used to ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... for the second quarter ended June 30, 2014 after ... host a conference call that day at 5:00 p.m. ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... April 29, 2011 Halozyme Therapeutics, Inc. (Nasdaq: ... products targeting the extracellular matrix , today announced ... on Friday, May 6, 2011 before the open of ... a conference call with the investment community at 8:00 ...
... SAN MATEO, Calif., April 29, 2011 ... patch purchased by 321 institutions, up from 239 in Q4 ... Qutenza product revenue Operational focus enables lower planned expense ... Czech Republic by Astellas NGX-1998 Phase 2 clinical trial ...
Cached Medicine Technology:Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6 2NeurogesX Reports First Quarter 2011 Results 2NeurogesX Reports First Quarter 2011 Results 3NeurogesX Reports First Quarter 2011 Results 4NeurogesX Reports First Quarter 2011 Results 5NeurogesX Reports First Quarter 2011 Results 6NeurogesX Reports First Quarter 2011 Results 7NeurogesX Reports First Quarter 2011 Results 8
(Date:8/1/2014)... 2014 As AndroGel lawsuits and testosterone ... E. Johnson, Jr. has been appointed as co-lead counsel ... testosterone medications. Since the Fall of 2013, Ron and ... diligently to investigate and prosecute the claims of men ... clots as a result of taking testosterone. As a ...
(Date:8/1/2014)... Growing prevalence of chronic ailments, ... are boosting healthcare market growth, although a reduction ... increasing generic consumption is a major challenge. , ... 2013, having grown at a Compound Annual Growth ... of the Health Transformation Program (Saglikta Donus, um ...
(Date:8/1/2014)... August 01, 2014 The "Antimicrobial ... such as Zinc Oxide, Titanium Dioxide, and Zinc ... & Construction, Food & Beverages, Textiles, and others), ... - Global Trends and Forecasts to 2018" analyzes ... drivers, opportunities, and trends in the diverse geographical ...
(Date:8/1/2014)... 2014 According to new market ... (Asia-Pacific, North America, Europe, & ROW), by Vehicle ... Type (Gasoline & Diesel), by After-Treatment Device (DPF, ... & Forecasts to 2019", defines and segments the ... of major countries in all the regions, and ...
(Date:8/1/2014)... NY August 1, 2014 The Cardiovascular ... and first report investigations that will be presented ... scientific symposium. TCT, the world,s premier educational meeting ... September 13 17, 2014 at the Walter ... Clinical research data presented at TCT often direct ...
Breaking Medicine News(10 mins):Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 2Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 4
... Nov. 28 GAB Robins is pleased to,announce that ... Adjusting,Sales for North American Operations. In this position, Ms. ... and will be responsible for,increasing business development opportunities for ... been with GAB Robins for seven years. Most recently, ...
... Nov. 28 In recognition of,National ... Inc., (http://www.HealthCentral.com ) today has launched ... informs online users about acne,aging skin, ... reliable medical information and a,community forum ...
... N.J., Nov. 28 RadPharm, Inc., a leading,provider ... announced,the completion of a $10 million Series B ... Ampersand Ventures, Adams Street,Partners and Tang Capital Management ... wealth of expertise in medical imaging and clinical,research, ...
... HUBBARD, Ohio, Nov. 28 NanoLogix, Inc. ... that the company has,submitted international patent applications ... China, India, Brazil, and the,EU (European Union). ... anticipated,global roll-out of the company,s BioNanoChannel(TM) rapid,bacteria/microorganism ...
... /Xinhua-PRNewswire-FirstCall/ -- China Yingxia,International, Inc. (OTC Bulletin ... industry engaged in the development, manufacture and,distribution ... care products in China, today announced that ... Asia institutional investor conference on,December 5, 2007 ...
... Patient Implanted in San Antonio, TX -, ORANGEBURG, ... began patient enrollment in a national diabetes clinical,trial of ... with type 2 diabetes who are overweight. The study ... United States., The 300-patient trial will evaluate the ...
Cached Medicine News:Health News:The HealthCentral Network Adds Skin Care Site to Its Web Properties 2Health News:RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital 2Health News:RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital 3Health News:NanoLogix Inc. Files Multiple International Patent Applications for BioNanoChannel(TM) and Hydrogen Bioreactor Technology 2Health News:China Yingxia to Present at the ICR XChange Asia Institutional Investor Conference 2Health News:MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight 2
POLYSORB™ sutures are composed of LACTOMER™ glycolide/lactide copolymer which is a synthetic polyester composed of glycolide and lactide (derived from glycolic and lactic acids)....
Surgitie&trade Single Use Ligating Loops with Delivery System...
ENDO SLIDE™ single use knot pusher with 12 units per box....
ENDO STITCH™ Single Use Loading Units....
Medicine Products: